Clinical and serological evaluation of a Pasteurella haemolytica A1 capsular polysaccharide vaccine

The purified capsular polysaccharide (CPS) of Pasteurella haemolytica A1 was examined for its ability to protect cattle from experimental challenge with logarithmic-phase P. haemolytica. Several preparations of P. haemolytica antigens were utilized in the experiment including CPS, log-phase P. haemolytica culture supernatant, P. haemolytica recombinant leucotoxin (rLKt) and various combinations of the above. CPS alone or in combination with culture supernatant or rLkt elicited no protection; rather, administration of CPS was associated with a high incidence of anaphylaxis (36% of calves). Although a classical biphasic humoral immune response to CPS could be detected in all calves that received this compound, this T-dependent response was not correlated with resistance to experimental challenge. The complexity of protective immunity in pneumonic pasteurellosis is emphasized by this study, and clinical anaphylaxis associated with response to CPS may be implicated in the pathogenesis of disease.